Ascletis Pharma (1672) Fundamentals 2026 — Revenue Analysis | SniperIQ
Ascletis Pharma (1672) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK$9.2B, trading at HK$8.73 on the HKSE. This SniperIQ fundamentals page covers Ascletis Pharma's valuation, profitability (net margin -17745.6%), revenue (¥2M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ascletis Pharma's market cap?
Ascletis Pharma (1672) has a market capitalization of approximately HK$9.2B, trading at HK$8.73 on the HKSE. Market cap moves with the live share price.
What is Ascletis Pharma's P/E ratio?
Ascletis Pharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ascletis Pharma?
Ascletis Pharma runs a net profit margin of -17745.6%, a gross margin of 26.0%, and an operating margin of -23853.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ascletis Pharma generate?
Ascletis Pharma reported revenue of ¥2M for fiscal year 2025, with net income of -¥360M and earnings per share (EPS) of -0.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Ascletis Pharma pay a dividend?
Ascletis Pharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Ascletis Pharma financially healthy?
Ascletis Pharma carries a debt-to-equity ratio of 0.00x and a current ratio of 15.05x, with a market beta of 0.40. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Ascletis Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ascletis Pharma (1672) the key facts are: market cap HK$9.2B, revenue ¥2M, 52-week range 7.95-19.86. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Ascletis Pharma's full fundamentals live
Get Ascletis Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.